Human Anti-NS1 Recombinant Antibody (clone ZKA35) (CAT#: FAMAB-1770CQ)

Figure 1 ZKA35 binds to a conformational and highly conserved site on ZIKV NS1.

Binding of ZKA35 mAb to Vero cells infected with H/PF/2013 ZIKV strain. ZKA35 and a control mAb (MPE8 directed to RSV F protein) were tested at 0.3 µg/mL, using mock- or ZIKV-infected cells 2 d postinfection. Cells were permeabilized with 0.5% saponin, and binding was determined using an anti-human IgG Alexa488-conjugated antibody in the presence of the Draq5 counterstain. Fluorescence was read using a high-throughput fluorometric microvolume assay technology (Mirrorball, TPP Labtech).

Balmaseda, A., Stettler, K., Medialdea-Carrera, R., Collado, D., Jin, X., Zambrana, J. V., ... & Corti, D. (2017). Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proceedings of the National Academy of Sciences, 114(31), 8384-8389.

Figure 2 Soluble NS1 inhibits ZKA35 binding to solid-phase ZIKV NS1.

Plotted is the percentage of ZKA35 mAb binding inhibition by two plasma samples from Swiss blood donor controls (ZIKV- and DENV-negative) that were spiked with increasing amounts of ZIKV NS1. The addition of exogenous NS1 to negative control plasma samples resulted in ZKA35 mAb binding inhibition when the concentration of NS1 exceeded 1 µg/mL.

Balmaseda, A., Stettler, K., Medialdea-Carrera, R., Collado, D., Jin, X., Zambrana, J. V., ... & Corti, D. (2017). Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proceedings of the National Academy of Sciences, 114(31), 8384-8389.